Showing 1301-1310 of 5771 results for "".
- CSI Dry Eye Software Announces Ken Barbet as New Chief Executive Officerhttps://modernod.com/news/csi-dry-eye-software-announces-ken-barbet-as-new-chief-executive-officer/2482754/Earlier this week, CSI Dry Eye Software, an artificial intelligence-based platform to aid dry eye disease management, announced Ken Barbet at the company’s new Chief Executive Officer (CEO). Mr. Barbet has 30 years of executive leade
- Outlook Therapeutics Announces Acceptance of Resubmitted BLA by FDA for ONS-5010 as a Treatment for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-acceptance-of-resubmitted-bla-by-fda-for-ons-5010-as-a-treatment-for-wet-amd/2482733/Outlook Therapeutics announced that the FDA has acknowledged receipt of the resubmission of the biologics license application (BLA) for ONS-5010 (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD. The FDA has determined that the BLA
- Opus Genetics Announces 1-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseaseshttps://modernod.com/news/opus-genetics-announces-1-month-clinical-data-from-pediatric-patient-in-phase-12-trial-of-opgx-lca5-gene-therapy-in-inherited-retinal-diseases/2482731/Opus Genetics announced 1-month clinical data from the first pediatric patient treated with its investigational gene therapy, OPGx-LCA5, in an ongoing phase 1/2 open-label trial. The therapy is aimed at treating LCA5-related inherited retinal disease.
- Sydnexis Announces Positive CHMP Opinion in Europe for Myopia Drug Candidate SYD-101https://modernod.com/news/sydnexis-announces-positive-chmp-opinion-in-europe-for-myopia-drug-candidate-syd-101/2482722/Sydnexis announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for its proprietary low-dose atropine formulation, SYD-101, for slowing the progression of pediatric m
- Pantheon Vision Announces Partnership with EyeDeal Medical to Develop Bioengineered Corneal Implanthttps://modernod.com/news/pantheon-vision-announces-partnership-with-eyedeal-medical-to-develop-bioengineered-corneal-implant/2482719/Pantheon Vision today announced a partnership with manufacturer EyeDeal Medical to develop an artificial, bioengineered corneal implant. Their goal, the company states, is to eliminate corneal blindness by removing the need for human donor corneal tissue. Corneal blindness is the
- Bausch + Lomb Announces Voluntary Recall of enVista IOLshttps://modernod.com/news/bausch-lomb-announces-voluntary-recall-of-envista-iols/2482717/In response to an increased number of reports of toxic anterior segment syndrome (TASS), Bausch + Lomb announced a voluntary recall of IOLs on its enVista platform, including the enVista Aspire and enVista Envy IOLs, and certain enVista monofocal lenses in the US. B+
- Unity Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in DMEhttps://modernod.com/news/unity-biotechnology-announces-topline-results-from-the-aspire-phase-2b-study-in-dme/2482712/Unity Biotechnology announced topline results from the phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The study results include data from all patients through 24 weeks, and the majori
- Nicox Announces Data Collection Complete, NCX 470 Phase 3b Whistler Glaucoma Trialhttps://modernod.com/news/nicox-announces-data-collection-complete-ncx-470-phase-3b-whistler-glaucoma-trial/2482709/Nicox announced today that the last patient completed their final visit in the Whistler phase 3b clinical trial investigating the efficacy of NCX470 to lower IOP. This marks the end of their
- Iantrek Announces Positive Efficacy and Safety Profile of its Bio-Interventional Technologyhttps://modernod.com/news/iantrek-announces-positive-efficacy-and-safety-profile-of-its-bio-interventional-technology-to-enhance-uveoscleral-outflow-in-glaucoma-patients/2482707/Iantrek Corporation today announced positive results from its 2-year prospective clinical study evaluating its bio-reinforced cyclodialysis technology. The study, published in Ophthalmology Science, affirms the safety and efficacy of Iantrek’s bio-interventional technology to enhance&n
- Staar Surgical Announces Restructure of Leadershiphttps://modernod.com/news/staar-surgical-announces-restructure-of-leadership/2482705/Staar Surgical announced a series of changes to their leadership structure. These changes come in an effort to better address marketing needs, according to Staar. Warren Foust, Chief Operating Officer, has been promoted to the newly created role of Preside